New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Check below for free stories on MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 17, 2014
16:36 EDTKNDGentiva Health rejects prior Kindred Healthcare proposal, receives alternate bid
Subscribe for More Information
15:42 EDTDEPODepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
09:37 EDTARNAActive equity options trading on open
Subscribe for More Information
08:39 EDTCVSCVS Caremark signs new affiliations with four major health care providers
CVS Caremark has entered into new clinical affiliations with four major health care providers in Connecticut, Texas, South Carolina and Louisiana. Through these clinical affiliations the patients of these health care providers will receive access to clinical support, medication counseling, chronic disease monitoring and wellness programs at CVS/pharmacy stores and MinuteClinic, the retail health care division of CVS Caremark.
08:03 EDTDEPODepomed appoints Srinivas Rao as Chief Medical Officer
Subscribe for More Information
07:42 EDTCVSCVS Caremark earnings could beat expectations, says Wells Fargo
Subscribe for More Information
07:18 EDTGMEDScoliosis Research Society to hold annual meeting
Subscribe for More Information
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
July 15, 2014
16:37 EDTDEPODepomed files automatic mixed securities shelf
Subscribe for More Information
16:34 EDTARNAArena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators
Arena Pharmaceuticals announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the U.S. Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2. Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
10:40 EDTARNAArena Pharmaceuticals receives USPTO patent for cannabinoid receptor modulators
Reference Link
July 14, 2014
16:23 EDTCVSCVS Caremark acquires Miami-based Navarro Discount Pharmacy
Subscribe for More Information
12:06 EDTKNDGentiva Health urges holders to take no action in response to Kindred offer
Subscribe for More Information
07:32 EDTKNDKindred Healthcare increases all-cash tender offer for Gentiva to $16 per share
Subscribe for More Information
07:32 EDTKNDKindred Healthcare increases all-cash tender offer for Gentiva to $16 per share
Subscribe for More Information
July 11, 2014
11:19 EDTBDSIOptions with decreasing implied volatility: BDSI CWH INFY MONT
Subscribe for More Information
July 10, 2014
11:01 EDTBDSIOptions with decreasing implied volatility: BDSI
Subscribe for More Information
08:08 EDTARNAArena Pharmaceuticals reports that Eisai increases sales force for Belviq
Arena Pharmaceuticals reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for Belviq by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the U.S.
July 9, 2014
08:17 EDTKNDGentiva Health says Kindred Healthcare offer 'substantially undervalues' company
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use